This study is testing a new oral medication called bezuclastinib for people with advanced systemic mastocytosis (AdvSM). This includes aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematologic neoplasm (SM-AHN), and mast cell leukemia (MCL). The study aims to find a safe and effective dose of bezuclastinib and see how well it works to shrink the disease. You may be able to join if you are 18 or older and have one of these advanced mastocytosis diagnoses with measurable disease.

Study design

This is an open-label, two-part Phase 2 study, meaning both you and your doctors will know you are receiving bezuclastinib. The study plans to enroll 140 participants.

What's involved

You would take bezuclastinib tablets continuously in 28-day cycles. The study will measure how well the treatment works over 18 months.

Compensation

Not stated in the trial record.

Follow-up

The main goals of the study are measured at 18 months after starting treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.